lamivudine HBV / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«1234567»
  • ||||||||||  lamivudine HBV / Generic mfg.
    Clinical, Journal:  Rapid Turnover of HBV cccDNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients. (Pubmed Central) -  Jun 22, 2021   
    Similarly, in lamivudine-resistant patients who switched to interferon therapy, serum HBV RNA population bearing 100% LAM mutations fully reversed back to wild type within 24~48 weeks. The genetic composition dynamics of serum HBV RNA and biopsy cccDNA in treated HBV patients indicates that cccDNA turnover occurs relatively rapidly (several months), offering a possibility of HBV cure with finite therapy through completely blocking cccDNA replenishment.
  • ||||||||||  ATI-2173 / Antios Therap
    Journal:  ATI-2173, A Novel Liver-Targeted Non-Chain Terminating Nucleotide for HBV Cure Regimens. (Pubmed Central) -  Jun 22, 2021   
    ATI-2173 activity was decreased by viral polymerase mutations associated with entecavir, lamivudine, and adefovir resistance, but not capsid inhibitor resistance mutations...Despite reduced plasma clevudine exposure, liver concentrations of the 5'-triphosphate were equivalent following ATI-2173 versus clevudine administration. By selectively delivering the 5'-monophosphate to the liver, while retaining the unique anti-HBV activity of the 5'-triphosphate, ATI-2173 may provide an improved pharmacokinetic profile for clinical use, reducing systemic exposure of clevudine and potentially eliminating skeletal myopathy.
  • ||||||||||  lamivudine HBV / Generic mfg.
    Review, Journal:  Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review. (Pubmed Central) -  Jun 5, 2021   
    In this review, we have discussed the different classes of nucleos(t)ide analogues used in the treatment of Hepatitis B virus and their relationship with the development of hepatocellular carcinoma. Furthermore, we discussed the effect of treatment of Hepatitis B virus with Nucleoside analogues (NAs) before, during and after surgery, chemoembolization, radiofrequency ablation, and chemotherapy for the treatment of hepatocellular carcinoma.
  • ||||||||||  lamivudine HBV / Generic mfg.
    [VIRTUAL] Molecular diversity of hepatitis B virus in HIV infected patients at Mbagathi District Hospital, Nairobi () -  May 27, 2021 - Abstract #IASHIV2021IAS_HIV_1288;    
    Lamivudine can significantly reduce the MTCT of HBsAg and HBV DNA of neonates during the third trimester of pregnancy without severe adverse events. Inadequate HBV co-management in HIV-HBV co-infected patients is likely to lead to the emergence and circulation of HBV escape mutants of interest to public health management and there may be high HBV drug resistance strains to available ART options in Kenya among HIV patients.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Clinical, Journal:  Prophylactic antiviral therapy for HBsAg-positive patients with DLBCL treated with rituximab-containing chemotherapy. (Pubmed Central) -  May 11, 2021   
    HBsAg-positive patients were divided into three groups based on anti-HBV prophylactic therapy: no nucleos(t)ide analogue (non-NA, n = 9), lamivudine (LAM, n = 20), and entecavir (ETV, n = 87)...Prophylactic use of entecavir would reduce the occurrence of HBV reactivation-related hepatitis and mortality in HBsAg-positive DLBCL patients receiving rituximab-containing chemotherapy. This trial was registered at UMIN clinical trial registry as #UMIN000025574.
  • ||||||||||  lamivudine HBV / Generic mfg.
    Journal:  Immunomodulatory mechanism of acyclic nucleoside phosphates in treatment of hepatitis B virus infection. (Pubmed Central) -  Apr 21, 2021   
    Only ANPs among NUCs have an additional pharmacological effect modulating LPS-mediated cytokine productions, which expect favorable immune responses towards HBV elimination. This additional immunomodulation by ANPs in PBMCs, as well as IFN-λ3 induction in the gastrointestinal tract, provides novel insights on HBV treatment.
  • ||||||||||  lamivudine HBV / Generic mfg.
    Journal, IO biomarker:  Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents. (Pubmed Central) -  Apr 20, 2021   
    Further studies revealed that compound 5k could induce HepG2 cells apoptosis by dose-dependently upregulating Bad and Bax expression and decreasing Bcl-2 and Bcl-xl protein level. Considering the potent anti-HBV and anti-HCC effect, compound 5k might be a promising lead to develop novel therapeutic agents towards HBV infection and HBV-induced HCC.
  • ||||||||||  lamivudine HBV / Generic mfg.
    Journal:  A Telomerase-Derived Peptide Exerts an Anti-Hepatitis B Virus Effect via Mitochondrial DNA Stress-Dependent Type I Interferon Production. (Pubmed Central) -  Apr 2, 2021   
    GV1001 inhibited HBV replication and hepatitis B surface antigen (HBsAg) secretion in a dose-dependent manner, showing synergistic antiviral effects with nucleos(t)ide analogs (NAs) including entecavir and lamivudine...We demonstrated that the cell-penetrating and cytosolic localization capacity of GV1001 results in antiviral effects on HBV infections via mtDNA stress-mediated IFN-I production. Thus, GV1001, a peptide proven to be safe for human use, may be an anti-HBV drug that can be synergistically used with nucleot(s)ide analog.
  • ||||||||||  lamivudine HBV / Generic mfg.
    Journal:  Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors. (Pubmed Central) -  Apr 2, 2021   
    Several compounds exhibited prominent anti-HBV activity compared to lead compound NZ-4 and positive drug Lamivudine, especially compound II-8b, showed the most prominent anti-HBV DNA replication activity (IC = 2.2 ± 1.1 μM)...Besides, II-8b can interact HBV capsid protein with good affinity constants (K = 60.0 μM), which is equivalent to lead compound NZ-4 ((K = 50.6 μM). The preliminary structure-activity relationships (SARs) of the newly synthesized compounds were summarized, which may help researchers to discover more potent anti-HBV agents.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Journal:  Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression. (Pubmed Central) -  Mar 25, 2021   
    The preliminary structure-activity relationships (SARs) of the newly synthesized compounds were summarized, which may help researchers to discover more potent anti-HBV agents. cIAP2 is involved in HBV-induced sorafenib resistance in liver cancer and anti-HBV treatments reduce cIAP2 expression and partially restore sorafenib sensibility.
  • ||||||||||  Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Dolutegravir plus lamivudine for the treatment of HIV-1 infection. (Pubmed Central) -  Mar 12, 2021   
    Moreover, this regimen is not feasible for HBV-coinfected individuals and should not be used during pregnancy. Currently, out of 2-drug regimens, DTG+3TC is one of clinicians' preferred option as it requires no pharmacokinetic booster, has a low risk of drug interaction, and does not require food intake.
  • ||||||||||  lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
    Clinical, Journal:  HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort. (Pubmed Central) -  Mar 7, 2021   
    The HBcAb-positive PLWH group demonstrated a significantly higher percentage of subjects with very low-level viremia at all time points after switching (6th month: <31% vs. 17.6%, p = 0.047; 12th month 34% vs. 27.5%, p = 0.001; 24th month 37% vs. 34.2, p = 0.003 of the HBcAb-positive and HBcAb-negative groups, respectively) and a higher percentage of subjects with detectable HIV RNA greater than 20 copies/mL 12 and 24 months after switching (12 months 32% vs. 11%, p = 0.001; 24 months 37% vs. 13.9%, p = 0.003 of the HBcAb-positive and HBcAb-negative groups, respectively). Logistic regression analysis showed that an increase in age of ten years (OR 2.48 (95% CI 1.58-3.89), p < 0.0001) and the presence of HBcAb positivity (OR 2.7 (5% CI 1.05-6.9), p = 0.038) increased the risk of detectability of HIV RNA by nearly three-fold after switching to 2DR-3TC.
  • ||||||||||  Tyzeka (telbivudine) / Novartis
    Journal:  Combination of saikosaponin c and telbivudine synergistically enhances the anti-HBV activity. (Pubmed Central) -  Feb 24, 2021   
    Logistic regression analysis showed that an increase in age of ten years (OR 2.48 (95% CI 1.58-3.89), p < 0.0001) and the presence of HBcAb positivity (OR 2.7 (5% CI 1.05-6.9), p = 0.038) increased the risk of detectability of HIV RNA by nearly three-fold after switching to 2DR-3TC. These in vitro results indicated that SSc acted as a promising nucleoside analogue adjuvant, especially for telbivudine in the therapeutic strategies against HBV infection.
  • ||||||||||  lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
    Journal:  Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans. (Pubmed Central) -  Feb 20, 2021   
    Sequence analysis also revealed a rare genotype G infection. While resource-limited settings may use lamivudine-based ART because of availability and low cost, antivirals with dual therapy against HBV and HIV (e.g., lamivudine and tenofovir) should always be recommended with the regular monitoring of HBV viremia levels.
  • ||||||||||  lamivudine HBV / Generic mfg.
    Journal, HEOR:  A Simple and Cost-Effective DNA Preparation Method Suitable for High-Throughput PCR Quantification of Hepatitis B Virus Genomes. (Pubmed Central) -  Feb 20, 2021   
    As a proof of concept, the assay was developed in 12-well plates to assess intra- and extracellular HBV genome equivalents (GEqs) of stably viral-replicating cell lines (e.g., HepAD38) and HBV-infected HepG2-NTCP cells, both treated with lamivudine (LMV), an HBV replication inhibitor...We devised a novel, robust, reproducible, high-throughput microtiter plate DNA preparation method suitable for quantifying HBV GEqs by qPCR analysis. This strategy enables rapid and convenient quantitative analysis of multiple viral DNA samples in parallel to investigate intracellular HBV replication and the secretion of DNA-containing viral particles.
  • ||||||||||  tenofovir disoproxil fumarate / Generic mfg.
    [VIRTUAL] A Rare Case of Nephrogenic Diabetes Insipidus From Tenofovir (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1536;    
    This case illustrates the importance of monitoring patients on tenofovir for signs of renal [tubular] dysfunction. In a polyuric patient on tenofovir, there should be a high index of suspicion for nephrogenic diabetes insipidus.
  • ||||||||||  lamivudine HBV / Generic mfg.
    [VIRTUAL] Fanconi's Syndrome and Dementia in a Patient With Chronic Hepatitis B Taking Nucleoside/ Nucleotide Analogue (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_919;    
    Because of LAM resistance, adefovir dipivoxil 10mg qd (ADV) was added in Jul 2007...TDF was then switched to tenofovir alafenamide (TAF) 25mg qd in Mar 2019...He was given Sinemet 25/100 and rivastigmine by neurologist with some improvement...For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
  • ||||||||||  lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
    Trial completion:  Long-Term Lamivudine Therapy for Chronic Hepatitis B (clinicaltrials.gov) -  Jun 30, 2017   
    P4,  N=50, Completed, 
    Trial completion date: Oct 2024 --> Feb 2024 Recruiting --> Completed
  • ||||||||||  lamivudine HBV / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
    Enrollment change, Trial termination:  A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma (clinicaltrials.gov) -  Apr 28, 2017   
    P3,  N=117, Terminated, 
    Trial primary completion date: Dec 2016 --> Jun 2017 N=309 --> 117 | Active, not recruiting --> Terminated; No cases enrollment
  • ||||||||||  Tyzeka (telbivudine) / Novartis
    Trial primary completion date, Post-transplantation:  Replacement of Lamivudine by Telbivudine to Improve Renal Function (clinicaltrials.gov) -  Feb 7, 2017   
    P2/3,  N=120, Completed, 
    N=309 --> 117 | Active, not recruiting --> Terminated; No cases enrollment Trial primary completion date: Dec 2015 --> Dec 2016